A Recurrent Homozygous Missense Dpm3 Variant Leads to Muscle and Brain Disease Publisher Pubmed



Nagy S^{1, 2} ; Lau T¹ ; Alavi S³ ; Karimiani EG⁴ ; Vallian J³ ; Ng BG⁵ ; Noroozi Asl S⁶ ; Akhondian J⁷ ; Bahreini A⁸ ; Yaghini O⁹ ; Uapinyoying P¹⁰ ; Bonnemann C¹⁰ ; Freeze HH⁵ ; Dissanayake VHW¹¹ Show All Authors
Source: Clinical Genetics Published:2022

Abstract

Biallelic pathogenic variants in the genes encoding the dolichol-phosphate mannose synthase subunits (DPM) which produce mannosyl donors for glycosylphosphatidylinositols, N-glycan and protein O- and C-mannosylation, are rare causes of congenital disorders of glycosylation. Pathogenic variants in DPM1 and DPM2 are associated with muscle–eye–brain (MEB) disease, whereas DPM3 variants have mostly been reported in patients with isolated muscle disease—dystroglycanopathy. Thus far, only one affected individual with compound heterozygous DPM3 variants presenting with myopathy, mild intellectual disability, seizures, and nonspecific white matter abnormalities (WMA) around the lateral ventricles has been described. Here we present five affected individuals from four unrelated families with global developmental delay/intellectual disability ranging from mild to severe, microcephaly, seizures, WMA, muscle weakness and variable cardiomyopathy. Exome sequencing of the probands revealed an ultra-rare homozygous pathogenic missense DPM3 variant NM_018973.4:c.221A>G, p.(Tyr74Cys) which segregated with the phenotype in all families. Haplotype analysis indicated that the variant arose independently in three families. Functional analysis did not reveal any alteration in the N-glycosylation pathway caused by the variant; however, this does not exclude its pathogenicity in the function of the DPM complex and related cellular pathways. This report provides supporting evidence that, besides DPM1 and DPM2, defects in DPM3 can also lead to a muscle and brain phenotype. © 2022 The Authors. Clinical Genetics published by John Wiley & Sons Ltd.